Byooviz®

ACTIVE PRINCIPLE:
ranibizumab

INDICATION:
wet macular degeneration
Macular edema
Diabetic retinopathy
degenerative myopia

DATE:
18/08/2021

STATUS:
Authorized

MORE INFORMATION